Australia: Does the act of applying for PBS listing constitute an offer to supply a pharmaceutical product?

Last Updated: 28 February 2017
Article by Lucy Hartland
Services: Intellectual Property & Technology
Industry Focus: Life Sciences & Healthcare

In pharmaceutical patent litigation, complex questions can arise about what type of conduct by a generic pharmaceutical company might amount to an infringement of a patentee's right to exploit its own invention, provided by the Patents Act 1990 (Cth) (Patents Act).

One question that has long had an unclear answer is whether an application for listing of a generic pharmaceutical on the Pharmaceutical Benefits Scheme (PBS) would amount to an 'offer to supply', in contravention of the patentee's right to exploit the originator version of the pharmaceutical. A recent decision of the Federal Court has shed new light on this issue.

In Apotex Pty Ltd v Warner-Lambert Company LLC (No 3),1 Nicholas J held that the proposed application for PBS listing would not be an 'offer to supply' within the definition of 'exploit' in the Patents Act, and would instead be no more than a mere preparatory step to enable exploitation at a later time.


In an earlier final decision2, Nicholas J held that Warner-Lambert Company LLC (together with four related entities, collectively 'Pfizer') was entitled to injunctive relief against Apotex Pty Ltd (Apotex) and Generic Partners Pty Ltd3 for threatened infringement of Australian Patent No. 714980 (Patent). The Patent concerned, among other things, the use of pregabalin for the treatment of pain. Pregabalin is currently marketed in Australia under the name Lyrica.

The decision

In determining the form of injunctive relief to which Pfizer was entitled, a key issue was whether Apotex's proposed application to its generic versions of Lyrica on the PBS would infringe the Patent.

Nicholas J observed that the 'method of treatment' claims of the Patent would not be exploited unless the specified method was performed during the term of the Patent. Further, section 117 of the Patents Act, concerning infringement by supply, did not apply in this scenario. This was because the application for PBS listing was not itself an infringing supply of a product that could be used to perform the method of treatment.

However, the question of whether Apotex's proposed PBS listing of its generic versions of Lyrica involved an exploitation of the Patent (and therefore an infringement) needed to be considered in the context of the other claims at issue. Pfizer argued that by applying for PBS listing of its generic pregabalin products, Apotex was exploiting the claimed invention by 'offering to sell or otherwise dispose of' products that resulted from the use of a method of manufacture encompassed by these claims. Nicholas J disagreed, holding that the application involved no more than an intention to engage with the statutory scheme by which Apotex would be able to offer its products at subsidised prices.

Nicholas J did not accept Pfizer's submission that the act of applying for PBS listing would otherwise involve an exploitation of the Patent. His Honour held that the application would be no more than a 'mere preparatory step' for Apotex's later supply of its products, although in an appropriate case that step may justify injunctive relief. Nicholas J distinguished other decisions dealing with the question of PBS listing and patent infringement on the basis that those decisions were made in the context of applications for interlocutory relief, in which it was necessary to also consider the 'balance of convenience' analysis (which essentially involves the court weighing up the inconvenience and injury to one party of granting an injunction against the inconvenience and injury to the other party of not doing so).

On that basis, Nicholas J ordered that the injunctive relief to which Pfizer was entitled did not include preventing Apotex from taking any steps to list its generic product on the PBS. Further, although not discussing issues of timing in detail, his Honour did not order that Apotex should be prevented from applying for PBS listing where that listing would occur before the Patent expired, commenting that whether such a listing would be made under those circumstances was a matter for the Minister of Health or his delegate.


When final orders for injunctive relief are made in cases where a pharmaceutical patent holder is otherwise entitled to an order preventing an infringer from infringing the patent in suit, it may not be possible to obtain an injunction against a generic competitor applying for a PBS listing of their product before the expiry of the patent. In other words, even where a generic competitor may be restrained from selling or supplying their product before a patent's expiry, they may not be prevented from taking the important preparatory step of seeking its listing on the PBS.

The effect of this decision on future applications for interlocutory injunctions in which a patentee seeks to restrain an alleged infringer from applying to list products on the PBS remains to be seen.


1Apotex Pty Ltd v Warner-Lambert Company LLC (No 3) [2017] FCA 94.
2 Apotex Pty Ltd v Warner-Lambert Company LLC (No 2) [2016] FCA 1238
3 Generic Partners Pty Ltd adopted Apotex's submissions and is not discussed further in this note.

This article is intended to provide commentary and general information. It should not be relied upon as legal advice. Formal legal advice should be sought in particular transactions or on matters of interest arising from this article. Authors listed may not be admitted in all states and territories

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Lucy Hartland
Similar Articles
Relevancy Powered by MondaqAI
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions